Vanguard Group
LXEO icon

Vanguard Group’s Lexeo Therapeutics LXEO Stock Holding History

Vanguard Group’s Portfolio LXEO Stock Details LXEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$38.7M Buy
3,894,310
+1,668,020
+75% +$15.2M ﹤0.01% 2306
2025
Q3 		$14.8M Buy
2,226,290
+223,424
+11% +$1.08M ﹤0.01% 2774
2025
Q2 		$8.05M Buy
2,002,866
+903,581
+82% +$2.97M ﹤0.01% 3022
2025
Q1 		$3.81M Sell
1,099,285
-19,594
-2% -$86.8K ﹤0.01% 3272
2024
Q4 		$7.36M Buy
1,118,879
+254,168
+29% +$2M ﹤0.01% 3103
2024
Q3 		$7.82M Buy
864,711
+234,792
+37% +$2.8M ﹤0.01% 3077
2024
Q2 		$10.1M Buy
629,919
+148,164
+31% +$2.15M ﹤0.01% 2912
2024
Q1 		$7.55M Buy
481,755
+65,573
+16% +$1.03M ﹤0.01% 3115
2023
Q4 		$5.59M Buy
+416,182
New +$5.17M ﹤0.01% 3244

Other funds holding LXEO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.71B AUM 374.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return